viewInvitrocue Ltd

InvitroCue Ltd to develop novel assay to detect pancreatic toxicity


Bio-analytics company InvitroCue Ltd (ASX:IVQ) will leverage its technology in modelling multi-organ toxicity by developing a novel assay to detect pancreatic toxicity.

The assay is part of a strategic collaboration with Switzerland’s InSphero AG, the world’s leading provider of assay-ready 3D microtissues for more predictive drug discovery and development.

The pancreatic toxicity assay is being developed to accelerate preclinical drug development and assessment of potential pancreatic toxicity associated with drug metabolism.

This builds on a previous agreement between InSphero and InvitroCue on in-vitro cell-based hepatotoxicity assay.

InvitroCue has already introduced a suite of disease-specific drug screening services related to non-alcoholic steatohepatitis, leishmaniasis and malaria.

In May, InvitroCue entered the oncology testing market for drugs to provide data points in selected solid tumours.

The company will use 3D cell-based technology to culture patient derived cancer cells in its laboratories for testing against a panel of approved drugs and new drug candidates.

InvitroCue’s technology may create a new market for personalised drug testing to improve individual treatment outcomes in selected solid tumours.

The company had $2 million cash at the end of the March 2016 quarter.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Invitrocue Ltd

Price: - AUD

Market: ASX
Market Cap: -


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Invitrocue Ltd named herein, including the promotion by the Company of Invitrocue Ltd in any Content on the Site, the Company receives from...



Invitrocue leads market with disruptive technology and personalised oncology...

Invitrocue Ltd (ASX:IVQ) chief executive officer Steven Fang speaks to Proactive Investors about the oncology-focused company's development of cancer treatments by testing specific drugs on laboratory-controlled micro-tumours.    "We've been able to take some of these really...

on 20/5/19

2 min read